CGH Microarrays (Chips)

CGI is currently developing and commercializing several CGH-based microarrays based on years of proprietary R&D programs. The cancer microarrays evaluate gene copy number variation (CNV) and gains and losses in DNA in order to provide accurate and timely diagnosis, determine prognosis and guide treatment decisions in selective malignancies including:

• Lymphoma is the 5^th most common type of cancer and accounts for 6% of all cancers in the US.

• Leukemia is the 9^th most common type of cancer in the US.

• Urogential (UG) Cancers account for 43% of cancers in men and 4% of cancers in women.

The Lymphoma Microarray (MatBa™) is currently in trials that are being conducted in collaboration with Long Island Jewish and Memorial Sloan Kettering Hospitals.

CGI Innovation, Knowledge, Leadership

CGI is focused on delivering products and services that drive the highest levels of patient value. To achieve this, we have developed a corporate culture that inspires innovation, respects knowledge and fosters leadership.

CGI Personalized Medicine Services

CGI’s dedicated staff takes pride in our specialized laboratory services, superior turnaround time (TAT), enhanced reporting, EMR integration, and ongoing research and development for new tests.

CGI’s full-service cancer genetic practice and path to innovation with research makes for optimal patient care management.